Study of Pulmonary Function Test in Bronchial Asthma Patients

Dr.Gurunath Birajdar,¹ Dr. Amey Paranjape,² Dr. Meera Nagavekar,³
¹Assistant Professor, Department of Physiology, B K L Walawalkar Rural Medical College, Hospital And
Research Centre, Sawarde, Chiplun, Maharashtra, India.
²Assistant Professor, Department of Pulmonary Medicine, B K L Walawalkar Rural Medical College, Hospital
And Research Centre, Sawarde, Chiplun, Maharashtra, India.
³Professor And Head, Department of Physiology, B K L Walawalkar Rural Medical College, Hospital And
Research Centre, Sawarde, Chiplun, Maharashtra, India.

Abstract: Asthma is a complex, recurrent disease of the airways that causes shortness of breath, wheezing and
cough (particularly at night or early in the morning). Asthma is episodic in nature and usually reversible, either
spontaneously or with treatment. The present study was undertaken to assess the pulmonary function status of
bronchial asthma patients. The results are based on 40 asthmatic patients and 40 healthy subjects (Control
group) in the age range of 20-70 years. To study pulmonary functions in asthmatic patients FEV1,FVC,
FEV1/FVC RATIO recorded on each subject. Pulmonary function test was carried out using RMS Helios 401
spirometer, Chandigarh. The present study showed decreased lung function parameters in asthma patients as
compared to control but the difference was statistically significant. So, knowledge of this study helpful in
treatment of asthma.

Keywords: Bronchial asthma, pulmonary function test, RMS Helios-401 spirometer.

I. Introduction

Asthma is a complex, recurrent disease of the airways that causes shortness of breath, wheezing, and
cough (particularly at night or early in the morning). Asthma is episodic in nature and usually reversible, either
spontaneously or with treatment. However, chronic inflammation, associated with persistent symptoms, may
contribute to airway remodeling that may not be completely reversible. Airflow limitation occurs as a result of
varying degrees of airway hyperresponsiveness, airway edema and bronchoconstriction.

Pulmonary function test (PFT), is a non-invasive test, used to detect air flow limitation and/or lung
volume restriction. Assessment of ventilator function is an important investigation because early detection of
functional impairment and its appropriate treatment will help to reduce morbidity and mortality related to
disease.

Long-term deterioration of lung function in asthmatic subjects has been described in various studies. For a long time it has been believed that asthma is characterized by totally reversible airway obstruction. Now it is
established that prolonged airway inflammation regulated by a variety of inflammatory cells and mediators is the central mechanism in the pathogenesis of asthma. Inflammation leads to injuries and repair including
regeneration and replacement by connective tissue. It has been hypothesized that chronic airway inflammation
can lead to airway remodeling and in the long term to irreversible airway obstruction. The consequence of this
process could be deterioration in pulmonary function. Asthma is characterized by the presence of reversible
airflow obstruction; however, irreversible airflow obstruction develops in some patients. Moreover, accelerated
loss of lung function over time has been reported in groups of patients with asthma in longitudinal prospective
and retrospective studies.

that clinically, airflow obstruction in asthma often is not fully reversible, and many asthmatic subjects
experience an accelerated and progressive loss of lung function over time. Lange et al (1998) proved that adults
with asthma have substantially greater declines in forced expiratory volume in 1s (FEV1) over time in
comparison with healthy subjects. Accelerated decline in lung function does not occur in all patients. The risk
factors identified for accelerated decline in lung function include young age, male gender (Cover et al, 2004),
duration of disease (Lee et al, 2007) more prominent eosinophilic airway inflammation (Cover et al, 2004),
asthma exacerbations (Bai et al, 2007), and smoking (Lee et al, 2007). Recent studies of patients with asthma
selected from the general population have shown increased mortality in subjects with reduced ventilator
function and have thus underlined the importance of preservation of normal lung function. (Silverstien, 1994;
Lange, 1996; Huovinen, 1997). In the present investigation an attempt has been made to study pulmonary
function of bronchial asthma patients. Little is known about lung function of bronchial asthma patients in this
part of the region as patients are treated on the basis of clinical history and signs and symptoms and their lung
function is rarely assessed.
II. Materials & Methods

The present cross sectional study has been conducted on bronchial asthma patients to study their pulmonary function status. 40 bronchial asthma patients and 40 healthy subjects (control) have been studied in the age range 20-70 years. Data on patients have been collected from B K L Walawalkar Rural Medical College & General Hospital, Sawarde, Chiplun, Ratnagiri. Selected patients and normal subjects were explained the purpose of the study and need of cooperation was emphasized. All the subjects participated in the study voluntarily. Pulmonary Function Tests (PFT): pulmonary function tests were done on all the subjects using RMS Helios-401 spirometer, Chandigarh. Following parameters were recorded for analysis.

1. **FEV1** - Forced expiratory volume in one second.
2. **FVC** - Forced vital capacity. The maximum volume of air forcibly expired from total lung capacity.
3. **FEV1/FVC RATIO** - ratio of forced expiratory volume of air expired during first second of FVC to forced vital capacity expressed as percentage.

III. Observation & Results

<table>
<thead>
<tr>
<th>PFT PARAMETERS</th>
<th>HEALTHY(CONTROL)</th>
<th>BRONCHIAL ASTHMA PATIENTS (CASES)</th>
<th>P-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>FEV1</td>
<td>2.37(0.57)</td>
<td>1.23(0.72)</td>
<td>0.001</td>
</tr>
<tr>
<td>FVC</td>
<td>2.59(0.63)</td>
<td>1.71(0.78)</td>
<td>0.001</td>
</tr>
<tr>
<td>FEV1/FVC RATIO</td>
<td>91.76(4.62)</td>
<td>69.37(18.16)</td>
<td>0.001</td>
</tr>
</tbody>
</table>

P value < 0.05 is statistically significant.
P value <0.001 is statistically highly significant.

All pulmonary function test parameters FEV1, FVC, FEV1/FVC RATIO reduced in bronchial asthma patients as compared to healthy subjects and the difference is statistically highly significant as indicated by p value.

**Figure1.** Bar diagram showing comparison in Pulmonary function test parameters between control and cases.

**Figure2.** Comparison of FEV1/FVC RATIO between control & cases.
IV. Discussion

Findings of the present study have shown that there is decline in the lung function in asthmatic patients as compared to control group. The difference in all lung function parameters in patients and control subjects are statistically significant. Present findings are thus in line with the perception that asthma is a chronic inflammatory disease in which ongoing tissue injury and repair may result in irreversible fibrotic changes in the airways leading to decline in lung functions. The results of previous studies of the decline in FEV1 in people with asthma are generally consistent with the present findings Fletcher and co-workers (1976) mean unadjusted decline in FEV1 of 22 ml. per year greater in men asthma than in men without asthma. More recent studies have evaluated FEV1 decline in large population samples (Ulrik et al, 1992 and Lange et al, 1998) and the result suggest that asthma as a significant impact on lung function decline. However in the Tucson lung study (Burrows et al, 1987) declines in FEV1 of less than 5 ml. per year were observed in adults with asthma. In a recent report of 25-year follow -up data on adults from a Dutch asthma clinic, more than 75 percent of the patients had FEV1 values below 90 percent of the predicted values at the final examination(Panhuysen et al, 1997). In a study by Zeiger et al (1999), the unadjusted annual decline was 80.1 ml. per year for asthma duration for FEV1 and 20.5 ml. per year for FVC in the whole study group. Also Peat et al (1987) found a mean loss of FEV1 in male non-smokers suffering from asthma of about 50 ml. per year compared with 35 ml./year in normal subjects. Silverstein et al (1994) Lange et al(1996) Huovinen et al (1997) show that a reduction in ventilator function leads to an increased mortality among asthmatic subjects. The preservation of normal lung function should be one of the aims of asthma therapy. Furthermore, in the present study findings, it is seen that smoking in asthma patients increases the severity and accelerates the decline in lung function. Thomson and Spears (2005) have reported that smoking and asthma are associated with poor symptom control and impaired therapeutic responses to antiasthma drugs.

Higher levels of smoking are seen in patients with asthma who attend emergency departments with exacerbations (Silverman et al, 2003) compared with asthmatic non-smokers, smokers with asthma have worse symptom control (Alhuis et al, 1999), an accelerated decline in lung function (Lange et al, 1998) and increased mortality rate (Marquette et al, 1992). Gallefoss and Bakke, 2003. Asthmatic smokers have more severe asthmatic symptoms, greater need for rescue medications, and worse indices of symptom control compared with asthmatics who have never smoked.


References


